



Erratum: Orally bioavailable proteasome inhibitors: preclinical development of PR-047

Drug Discov. Today 14 (2009) 905–906

In the article 'Orally bioavailable proteasome inhibitors: preclinical development of PR-047' by Kevin Peese, which was published in the September issues of *Drug Discovery Today*, a compound that is currently in phase II trials for the treatment of primary brain

cancer was incorrectly referred to as 'avixa'. The correct name of the compound is 'Azixa'. *DDT* apologizes to readers for any confusion caused by the error.